SI1926813T2 - Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe - Google Patents

Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe

Info

Publication number
SI1926813T2
SI1926813T2 SI200632094T SI200632094T SI1926813T2 SI 1926813 T2 SI1926813 T2 SI 1926813T2 SI 200632094 T SI200632094 T SI 200632094T SI 200632094 T SI200632094 T SI 200632094T SI 1926813 T2 SI1926813 T2 SI 1926813T2
Authority
SI
Slovenia
Prior art keywords
isolation
cell population
immunoregulatory activity
administration procedure
administration
Prior art date
Application number
SI200632094T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1926813T1 (sl
Inventor
Dirk Buscher
De La Pena Manuel Angel Gonzalez
Mora Mario Delgado
Original Assignee
Tigenix S A U
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1926813(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tigenix S A U, Consejo Superior Investigacion filed Critical Tigenix S A U
Publication of SI1926813T1 publication Critical patent/SI1926813T1/sl
Publication of SI1926813T2 publication Critical patent/SI1926813T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200632094T 2005-09-23 2006-09-22 Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe SI1926813T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077186 2005-09-23
EP06777197.2A EP1926813B2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses
PCT/EP2006/009244 WO2007039150A2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses

Publications (2)

Publication Number Publication Date
SI1926813T1 SI1926813T1 (sl) 2016-10-28
SI1926813T2 true SI1926813T2 (sl) 2019-11-29

Family

ID=37708240

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632094T SI1926813T2 (sl) 2005-09-23 2006-09-22 Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe

Country Status (19)

Country Link
US (5) US20090130067A1 (enExample)
EP (4) EP2340847B1 (enExample)
JP (2) JP5925408B2 (enExample)
KR (2) KR20080048555A (enExample)
CN (2) CN101313062A (enExample)
AU (1) AU2006299144A1 (enExample)
CA (2) CA2623353C (enExample)
CY (1) CY1117972T1 (enExample)
DK (1) DK1926813T4 (enExample)
ES (2) ES2589311T5 (enExample)
HU (1) HUE030503T2 (enExample)
IL (3) IL190363A0 (enExample)
LT (1) LT1926813T (enExample)
MX (1) MX342474B (enExample)
PL (1) PL1926813T5 (enExample)
PT (1) PT1926813T (enExample)
SG (3) SG165418A1 (enExample)
SI (1) SI1926813T2 (enExample)
WO (1) WO2007039150A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
ES2804472T3 (es) 2005-12-13 2021-02-08 Harvard College Estructuras para trasplante celular
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
EP2282748B1 (en) 2008-03-28 2016-11-09 Stemcyte, Inc. Treatment of brain damage using umbilical cord blood cells
HRP20180282T1 (hr) * 2008-04-17 2018-03-23 Io Biotech Aps Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
EP2204442A1 (en) * 2008-10-01 2010-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of enriching stem cells in culture
GB0820397D0 (en) 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
CN107007626A (zh) 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
CA2768552A1 (en) * 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
IN2012DN02764A (enExample) 2009-08-31 2015-09-18 Amplimmune Inc
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2012048165A2 (en) 2010-10-06 2012-04-12 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
JP6018081B2 (ja) 2011-01-12 2016-11-02 ティジェニクス エス．エー．ユー． 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞
ES2479565T1 (es) * 2011-03-11 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos
WO2012149046A1 (en) * 2011-04-25 2012-11-01 University Of Southern California Methods and compositions for improved tissue regeneration by suppression of interferon -gamma and tumor necrosis factor-alpha
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
EP2710122B1 (en) 2011-05-19 2021-03-31 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
AU2014296259B2 (en) 2013-07-30 2017-04-27 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
RU2736495C2 (ru) * 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3160481B1 (en) 2014-06-30 2020-09-09 TiGenix, S.A.U. Mesenchymal stromal cells for treating sepsis
US20170136065A1 (en) 2014-06-30 2017-05-18 Tigenix S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
KR101675521B1 (ko) * 2014-07-11 2016-11-17 대한민국 인돌아민 2,3-디옥시게나아제를 이용하여 인터페론-감마의 발현을 조절하는 방법
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
EP3419635B1 (en) 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
WO2019174842A1 (en) 2018-03-13 2019-09-19 Oxacell Ag Cell products with improved stability and uses thereof
AU2019287353A1 (en) 2018-06-15 2021-02-04 NextPhase Therapeutics, Inc. Pharmaceutical composition for dermatology and uses thereof
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN113490503A (zh) * 2019-05-21 2021-10-08 艾默生物医学股份有限公司 间质干细胞于治疗免疫相关疾病的用途
CA3168945A1 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
ATE247933T1 (de) 1994-06-06 2003-09-15 Univ Case Western Reserve Biomatrix für geweberegenaration
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
ATE478135T1 (de) * 1997-12-02 2010-09-15 Artecel Sciences Inc Differenzierung in osteoblasten der fettgewebe- stromalen zellen und ihre verwendungen
AU1628599A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan
DE69916807T2 (de) 1998-02-04 2005-01-13 The General Hospital Corp., Boston Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
PT1066060E (pt) 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
IL145002A0 (en) 1999-03-10 2002-06-30 Univ Pittsburgh Adipose-derived stem cells and lattices
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
WO2001039784A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
EP1372398B1 (en) 2001-02-23 2013-07-10 The University of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatement and repair
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
CA2466880A1 (en) 2001-11-09 2003-05-15 Artecel Sciences, Inc. Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
CA2489212C (en) 2002-06-14 2012-08-14 Cartela Ab Marker for stem cells and its use
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
WO2004090095A2 (en) * 2003-04-01 2004-10-21 University Of Southern California Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
CA2809195C (en) 2003-04-01 2014-05-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
ES2265199B1 (es) * 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
EP1641915B1 (en) 2003-06-27 2016-07-27 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
WO2005035738A1 (en) 2003-10-07 2005-04-21 Biomaster Inc. Cell differentiation of adipose-derived precursor cells
KR100821128B1 (ko) 2003-11-04 2008-04-14 가부시키가이샤 바이오마스타 지방 조직으로부터 줄기세포를 생성하는 방법 및 시스템
WO2005062857A2 (en) 2003-12-24 2005-07-14 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
CA2552891A1 (en) * 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity
EP2824175B2 (en) 2004-03-22 2020-10-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
WO2006029347A2 (en) 2004-09-03 2006-03-16 University Of Maryland, Baltimore Integrin cd18 is a novel stromal stem cell marker and functions to promote osteogenesis
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
JPWO2009031606A1 (ja) 2007-09-07 2010-12-16 日本ケミカルリサーチ株式会社 関節炎治療及び予防剤
RU2010109698A (ru) 2007-09-19 2011-09-27 Плуристем Лтд. (Il) Адгезивные клетки жировой ткани или плаценты и их использование в лечебных целях
US20100247577A1 (en) 2007-10-17 2010-09-30 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
CN107007626A (zh) 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
JP6018081B2 (ja) 2011-01-12 2016-11-02 ティジェニクス エス．エー．ユー． 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞
ES2479565T1 (es) 2011-03-11 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
JP6567430B2 (ja) 2013-03-15 2019-08-28 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー
US20160120910A1 (en) 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
CN107723274B (zh) 2021-05-07
MX342474B (es) 2016-09-30
KR20080048555A (ko) 2008-06-02
CA2953782A1 (en) 2007-04-12
DK1926813T4 (da) 2019-08-19
US12186344B2 (en) 2025-01-07
EP1926813A2 (en) 2008-06-04
KR101536239B1 (ko) 2015-07-13
SG10201400793RA (en) 2014-08-28
CY1117972T1 (el) 2017-05-17
PL1926813T3 (pl) 2017-01-31
IL246494B (en) 2021-09-30
US20090130067A1 (en) 2009-05-21
JP6089004B2 (ja) 2017-03-01
ES2751692T3 (es) 2020-04-01
EP3184631A1 (en) 2017-06-28
EP2340847A2 (en) 2011-07-06
EP2340847B1 (en) 2025-11-05
EP1926813B2 (en) 2019-05-22
PT1926813T (pt) 2016-09-06
SG165418A1 (en) 2010-10-28
SG10202001007TA (en) 2020-03-30
KR20140003631A (ko) 2014-01-09
AU2006299144A1 (en) 2007-04-12
LT1926813T (lt) 2016-11-10
ES2589311T5 (es) 2020-02-14
JP2009508507A (ja) 2009-03-05
SI1926813T1 (sl) 2016-10-28
CA2623353C (en) 2017-02-21
US20150224146A1 (en) 2015-08-13
EP3184630B1 (en) 2019-07-17
IL246494A0 (en) 2016-08-31
EP2340847A3 (en) 2016-11-09
WO2007039150A2 (en) 2007-04-12
US20170296593A1 (en) 2017-10-19
IL228670A0 (en) 2013-12-31
WO2007039150A3 (en) 2007-08-23
HUE030503T2 (en) 2017-05-29
JP2014221045A (ja) 2014-11-27
US20220313742A1 (en) 2022-10-06
PL1926813T5 (pl) 2019-11-29
CA2953782C (en) 2023-09-12
US20170296592A1 (en) 2017-10-19
US9943550B2 (en) 2018-04-17
ES2589311T3 (es) 2016-11-11
JP5925408B2 (ja) 2016-05-25
EP3184630A1 (en) 2017-06-28
IL228670A (en) 2017-06-29
CN101313062A (zh) 2008-11-26
IL190363A0 (en) 2011-08-01
CN107723274A (zh) 2018-02-23
CA2623353A1 (en) 2007-04-12
EP1926813B1 (en) 2016-06-08
DK1926813T3 (en) 2016-09-19
EP3184631B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
SI1926813T2 (sl) Celična populacija z imunoregulatorno aktivnostjo, postopek za izolacijo in uporabe
BRPI0720342A2 (pt) preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
ME01942B (me) Jedinjenja, preparati i metode
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
DK1905117T3 (da) Forbedrede perfluorerede membraner og forbedrede elektrolytter til redoxceller og batterier
EP1885859A4 (en) ELECTROPORATION AND TRANSFER OF MASS REGULATED THROUGH CELLULAR TISSUE MEMBRANES
WO2009051717A3 (en) Human factor ix variants with an extended half life
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
PT2205721T (pt) Células tr1, células-tronco mesenquimais e usos das mesmas
DE602005008893D1 (de) Brennstoffzellenstapel und diesen enthaltendes Brennstoffzellensystem
DE602006018990D1 (de) Membranelektrolyt und verbindungsprodukt und festpolymer-elektrolyt-brennstoffbatterie
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
DK2341147T3 (da) Præprimitive stribe- og mesendodermceller
CY1111769T1 (el) Παρασκευη κυτταρων
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
FI20040971L (fi) Solujen kasvatusalusta ja sen käyttö
DE602006013921D1 (de) Brennstoffzelle und Brennstoffzellenanalage
EP1766389A4 (en) METHOD OF ISOLATING CELLS
FI20055003L (fi) Järjestely ja menetelmä polttokennolaitteistossa
EP1975947A4 (en) ELECTROLYTE MEMBRANE AND FUEL CELL THEREFOR
DE602006020005D1 (de) Elektrochemische Zellenstruktur und dessen Herstellung
EP1889424A4 (en) MESSAGE TRANSMISSION IN PAGE MODE
DE602006017461D1 (de) Brennstoffzellenstapel und Brennstoffzellensystem
EP1907533A4 (en) PROGENITOR CELLS AND USES THEREOF
DK2084266T3 (da) Cellekultursystem, fremgangsmåde til fremstillingen deraf og anvendelse i prækliniske undersøgelser